The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use insulin.

DexCom reported that CONNECT data showed G7 improved HbA1c and time in range in Type 2 diabetes. DexCom's trial delivered Level A evidence for CGM use in adults with Type 2 diabetes not on insulin.

DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of ...

DexCom Inc. DXCM stock is trading higher on Monday after the diabetes management company reported positive results from its ...

Smart ring maker Oura and glucose monitoring giant Dexcom just struck a partnership that will allow the companies' products to work together, with the goal being to help users see how nutrition and ...

For those in the diabetes community who’ve dreamed about seeing their in-the-moment blood sugar readings and trend data right on their smartwatch or bike computer while exercising, Dexcom and Garmin ...

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C ...